Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Van Cutsem, Eric; Martinelli, Erika; Cascinu, Stefano; F. Sobrero, Alberto; Banzi, Maria; Seitz, Jean‐François; Barone, Carlo; Ychou, Marc; Peeters, Marc; Brenner, Baruch; Hofheinz, Ralf‐Dieter; Maiello, Evaristo; André, Thierry; Spallanzani, Andrea; García‐Carbonero, Rocio; Arriaga, Yull; Verma, Udit; Grothey, Axel; Kappeler, Christian; Miriyala, Ashok; Kalmus, J.; Falcone, Alfredo; Zaniboni, Alberto

doi:10.1634/theoncologist.2018-0072

Public

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Published in The Oncologist • Sep 6, 2018

Authors:

Eric Van Cutsem

Erika Martinelli

Stefano Cascinu

Abstract

BACKGROUND: In the phase III CORRECT trial, regorafenib significantly improved survival in treatment-refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization. METHODS...

Subject

Regorafenib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!